stockrow
Saturday 7 November 2026
Export NBTX’s income statement to Excel — free account
Nanobiotix S.A. - Sponsored ADR
NBTX Healthcare Biotechnology
Nanobiotix S.A. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $36.9 million.
30.60
0.58
+1.93%
Follow NBTX
Alert me
Nanobiotix S.A. - Sponsored ADR (NBTX) P/E ratio
Nanobiotix S.A. - Sponsored ADR has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2021 | 0.0× | — |
| Dec 2020 | 0.0× | — |
| Jun 2020 | 0.0× | — |
| Dec 2019 | 0.0× | — |
| 2 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NUVB Nuvation Bio Inc. compare | n/m |
| SLS SELLAS Life Sciences Group, Inc. compare | n/m |
| RARE Ultragenyx Pharmaceutical Inc. compare | n/m |
| KLRA Kailera Therapeutics, Inc. compare | n/m |
| NTLA Intellia Therapeutics, Inc. compare | n/m |
| NBTX Nanobiotix S.A. - Sponsored ADR | n/m |
| PGEN Precigen, Inc. compare | 60.3× |
| BRVE Braveheart Bio, Inc. compare | — |
| ADRX ADARx Pharmaceuticals, Inc. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)